Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine (UCI)
mi
from
Orange, CA
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine (UCI)
mi
from
Orange, CA
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Central Coast Medical Oncology Corporation
mi
from
Santa Maria, CA
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Central Coast Medical Oncology Corporation
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California Los Angeles (UCLA)
mi
from
Santa Monica, CA
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California Los Angeles (UCLA)
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Regional Hospital
mi
from
Hollywood, FL
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Regional Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hope Women's Cancer Center
mi
from
Asheville, NC
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hope Women's Cancer Center
mi
from
Asheville, NC
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UNIMED Medical Institute
mi
from
Hong-Kong,
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UNIMED Medical Institute
mi
from
Hong-Kong,
Click here to add this to my saved trials
Testing a Spanish Version of a Patient Toxicity Questionnaire
Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Testing a Spanish Version of a Patient Toxicity Questionnaire
Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marrero, LA
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marrero, LA
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Omaha, NE
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
East Setauket, NY
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
East Setauket, NY
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated:  12/31/1969
mi
from
Kogarah,
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Status: Enrolling
Updated: 12/31/1969
mi
from
Kogarah,
Click here to add this to my saved trials
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford Women's Cancer Center
mi
from
Stanford, CA
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford Women's Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center - Hospital of the University of Pennsylvania at Perelman Center for Advanced Medicine
mi
from
Philadelphia, PA
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center - Hospital of the University of Pennsylvania at Perelman Center for Advanced Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Complexo Hospitalario Universitario A Coruña
mi
from
A Coruna,
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Complexo Hospitalario Universitario A Coruña
mi
from
A Coruna,
Click here to add this to my saved trials
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope- South Pasadena Cancer Center
mi
from
South Pasadena, CA
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope- South Pasadena Cancer Center
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern
mi
from
Dallas, TX
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer
Impact of Body Weight on the Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide in Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
UTsouthwestern medical center
mi
from
Dallas, TX
Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer
Impact of Body Weight on the Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide in Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
UTsouthwestern medical center
mi
from
Dallas, TX
Click here to add this to my saved trials
Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy
Feasibility of Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy
Feasibility of Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Evaluation of BIS for Quantification of Lymphedema
Evaluation of the Validity of BIS as a Tool for Quantification of Lymphedema Through Comparison With Perometry and Self-Report
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Evaluation of BIS for Quantification of Lymphedema
Evaluation of the Validity of BIS as a Tool for Quantification of Lymphedema Through Comparison With Perometry and Self-Report
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates - Biltmore Cancer Center
mi
from
Phoenix, AZ
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates - Biltmore Cancer Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sedona Medical Center
mi
from
Sedona, AZ
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sedona Medical Center
mi
from
Sedona, AZ
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates
mi
from
Tucson, AZ
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
NEA Baptist Clinic-Matthews
mi
from
Jonesboro, AR
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
NEA Baptist Clinic-Matthews
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Anaheim Medical Center
mi
from
Anaheim, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Anaheim Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Group - Baldwin Park
mi
from
Baldwin Park, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Group - Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Epic Care-Dublin
mi
from
Dublin, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Epic Care-Dublin
mi
from
Dublin, CA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northbay Cancer Center
mi
from
Fairfield, CA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northbay Cancer Center
mi
from
Fairfield, CA
Click here to add this to my saved trials